Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Goorha, S., Lancet, J., Maness, L. J., Marcucci, G., Millenson, M. M., Moore, J. O., Ravandi, F., Shami, P. J., Smith, B. D., Stone, R. M., Strickland, S. A., Tallman, M. S., Wang, E. S., Naganuma, M., Gregory, K. M. 2012; 10 (8): 984-1021


Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age = 65 years) adult patients, and key supportive care considerations.

View details for PubMedID 22878824